The Big Picture of IBD
An Interactive Experience Highlighting Recent Clinical Advances
Clinical Practice Guidelines
ACG Clinical Guideline: Management of Crohn's Disease in Adults.
Lichtenstein GR, et al. Am J Gastroenterol. 2018;113(4):481-517.
Ulcerative Colitis Care Pathway.
Dassopoulos T, et al. Gastroenterology. 2015;149(1):238-45.
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
Peyrin-Biroulet L, et al. Am J Gastroenterol. 2015;110(9):1324-1338.
European Crohn’s and Colitis Organisation guidelines
References for IBD management in Europe. The guidelines are updated regularly and available for download on the ECCO Website
Maasur C, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications.
J Crohns Colitis. 2018.
Sturm A, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects.
J Crohns Colitis. 2018.
Patient Resources
Inflammatory Bowel Disease (IBD): What Is It?
Centers for Disease Control and Prevention (CDC)
Crohn’s and Colitis Foundation
Types of Medications for Crohn's Disease and Ulcerative Colitis
Treatment Decisions: Shared Decision Making
Advocacy Tools and Resources
Crohn’s Disease and Ulcerative Colitis: Emotional Factors Q & A
The National Institute of Diabetes and Digestive and Kidney Diseases Health Information
Suggested Readings
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Colombel JF, et al. Lancet. 2018;390(10114):2779-2789.
Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
Coskun M, et al. Pharmacol Res. 2013;76:1-8.
Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies.
Kim DH, Cheon JH. Immune Netw. 2017;17(1):25-40.
The future of Janus kinase inhibitors in inflammatory bowel disease.
De Vries LCS, et al. J Crohns Colitis. 2017;11(7):885-893.
JAK inhibition in inflammatory bowel disease.
Olivera P, et al. Expert Rev Clin Immunol. 2017;13(7):693-703.
Tofacitinib as induction and maintenance therapy for ulcerative colitis.
Sandborn WJ, et al. N Engl J Med. 2017;377(5):496-497.
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Vermeire S, et al. Lancet. 2017;389(10066):266-275.
An Interactive Experience Highlighting Recent Clinical Advances
Relevant Resources
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Evolving Strategies for Diagnosis and Long-Term Management
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Targeting Immune Dysregulation and Delivering Comprehensive Care
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Got it? Treat it!
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Using Imaging to Improve Patient Outcomes
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
The Emerging Role of the Diabetologist
Key Issues Impacting OB/GYN Practice
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
Hot Topics in HBV, HCV, and NASH
Emerging Concepts in Patient Management
Building Your Understanding to Combat a Growing Problem
Debates & Discussions on the Evolving Role of JAK Inhibitors
Why It Matters in OB/GYN Practice Today
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
The Evolving Role of JAK Inhibitors
Understanding the Growing Syndemic — Opioids, HCV, and HIV
Unpacking the Evidence for Their Use Today and Tomorrow
Appraising the Therapeutic Armamentarium in Moderate and Severe Disease
The PCP’s Role in HCV Elimination
Unlocking Novel Paths to Patient Care
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
The Increasing Role of JAK Inhibitors
An Interactive Learning Experience
Unlocking Novel Paths to Patient Care
New Pathways to Patient Management
A Focus on Clinical Evidence and Guideline Recommendations
A Multidisciplinary Online Mini-Curriculum
Volume 1: A Guided Tour of the Evidence Driving Selection of First-line Advanced Therapies in Moderate to Severe IBD
New Avenues to the Management of Severe Asthma
Establishing Clinical Readiness Through Mentored Learning
Interdisciplinary Strategies for Adult and Pediatric Patients
